Tempest Therapeutics, Inc. (TPST): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise Brisbane, CA , October 14, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T th
- Person
- John W. Frederick
- Title
- board of directors
- Action
- appointed
- Effective
- October 14, 2026
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The 8‑K filing provides the first public disclosure of the board appointment, a standard corporate governance event with limited immediate price impact.
Market read
A routine board appointment that offers modest governance improvement but is unlikely to move the stock significantly.
What to watch
Frederick's network could facilitate future capital raises, which may become material if financing needs increase.
Background
Tempest Therapeutics is a clinical‑stage biotech developing in‑vivo CAR‑T therapies for cancer and autoimmune diseases.
Ticker impact
Tempest Therapeutics filed an 8‑K announcing the appointment of John W. Frederick to its board of directors.
likely modest upside as the market perceives the board addition as strengthening governance
Board appointments are typically low‑impact events; however, Frederick's finance background could support future financing activities.
Market effects
Minimal; the biotech sector may note the governance change but no immediate operational impact.
Limited to U.S. investors in TPST; no broader regional effect.
Low; the filing is a routine corporate governance update.
Counterpoint
The appointment may be a distraction; investors could focus on clinical data rather than board changes.
Key entities
- companyTempest Therapeutics, Inc.
Biotech firm developing CAR‑T therapies (NASDAQ: TPST).
- personJohn W. Frederick
New board member with extensive finance and capital‑markets experience.